LOBBYIST

David Lachmann

← Back to lobbyists

78ACTIVITIES

1ORGS REPRESENTED

53BILLS

Organizations represented

Orgs whose LD-2 filings list David as an active lobbyist, sorted by activity volume.

Biotechnology Innovation Organization78 activities

Bills they file on

S. 109732 mentions

S. 52732 mentions

S. 109632 mentions

S. 104131 mentions

S. 227630 mentions

S. 4330 mentions

H.R. 648529 mentions

H.R. 326928 mentions

S. 374128 mentions

H.R. 167222 mentions

H.R. 126219 mentions

S. 86417 mentions

S. 109517 mentions

S. 265817 mentions

S. 52616 mentions

+ 38 more bills referenced in their activities

Topics in Filings

386

Policy topics David files on across all their LD-2 activities.

CMMI: GLOBE and GUARD Models×70

Interagency Patent Coordination and Improvement Act×65

Preserve Access to Affordable Generics and Biosimilars Act×63

Prescription Pricing for the People Act×60

National Coverage Determination×58

Stop STALLING Act×57

Most Favored Nation Drug Pricing Proposals×57

International Pricing Policies×56

Clinical Trial Data in China×50

Big Savings Act×44

Pharmacy Benefit Manager Transparency Act×42

CMMI Authority×42

Show all 386 topics (+374 more) ▾

Maintaining Investments and New Innovation×40

Affordable Prescriptions for Patients Act×38

Drug Pricing×35

Biosimilar Red Tape Elimination Act×34

Lowering Drug Costs for American Families Act×34

SAFE STEP Act×34

Medicare Drug Price Negotiation Act×33

Modernizing and Ensuring PBM Accountability×33

Medicaid VBPs for Patients×32

Increasing Transparency in Generic Drug Application×31

Medical Countermeasure Priority Review Voucher Reauthorization×30

Data Privacy Working Group Draft×28

Pediatric Priority Review Voucher×28

340B Rebate Rule×28

Biosecurity Modernization×28

Restrictions on Intellectual Property Rights×26

BIOSECURE Act×23

Vaccine Injury Compensation Program×23

Vaccines and Infectious Diseases×22

House GOP RFI on Supply Chain×21

Medication Affordability and Patient Integrity Act×21

Interchangeability and Pharmacy Substitution×21

Promising Pathway Act×21

Quality & Distribution×21

Advanced Manufacturing×21

Drug Shortages×21

Supply Chain Integrity and Traceability×21

Patient Cost-Sharing and Implementation×21

Alternative Payment Arrangements for Gene Therapies×21

Drug Benefit Design×21

National Defense Authorization Act×21

Adult Immunization×21

MCM Manufacturing & Capacity×21

MCM PRV Reauthorization×21

Vaccine Safety net and Vaccine Infrastructure×21

Value of Vaccines and Vaccine Confidence×21

Helping Startups Continue to Grow Act×21

Antimicrobial Resistance×21

Mandating Exclusive Review of Individual Treatments×21

American Privacy Rights Act×20

CICP×20

Pricing and Rebates×20

Drug Supply Chain Management×20

Supply Chain Issues×20

Medicare Part B Physician-Administered Products×20

Patient Cost-Sharing and Smoothing×20

Support of Patient Premiums and Cost-Sharing Obligations×20

Maternal Immunization×20

Program Implementation & Oversight×20

Orphan Drug Tax Credit×20

Vaccine Injury Compensation Modernization×20

Bio COMPETES×19

Accelerated Approval Artificial Intelligence×19

Average Manufacturer Price Calculations×19

VICP Loopholes×19

Let Injured Americans Be Legally Empowered×19

Vaccine Access Improvement Act×19

Alternative Funding Programs×19

Access to Innovative Treatments Act×19

Bayh-Dole Act×18

Drug Patenting×18

Section 101 Modernization×18

Genetic Resources, and Associated Traditional Knowledge×18

TRIPS Waiver×18

Development and Procurement Issues×18

MCM PRV Program Reauthorization×18

WHO Pandemic Preparedness Accord Biosimilars×18

Development and Procurement×18

Funding for Strategic National Stockpile×18

R&D Funding for Medical Countermeasures×18

Value-based Contracting and Communications×18

Vaccine and Antimicrobial Resistance Product Development and Incentives×18

Accredited Investor Definition Review Act×18

Equal Opportunity for All Investors Act×18

CFIUS and Foreign Investment Drug Pricing×18

China Biotechnology Regulations×18

Pharmacy Benefit Managers Artificial Intelligence×17

Treaty on Intellectual Property×17

Risky Research Review Act×17

Reimbursement Cell & Gene Therapy×17

ORPHAN Cures Act×17

Accredited Investor Definition×17

FY 2026 Appropriations for Agencies×17

Centers for Disease Control and Prevention×17

Health Resources and Services Administration×17

HHS Office of Infectious Disease and HIV/AIDS Policy×17

Biodefense/Biomedical/Emergency Preparedness Research×17

Influenza Planning & Response×17

Prescription Drug User Fee Act×17

Project Bioshield×17

FDA Hiring Flexibility×17

DRUG Act×17

FDA Modernization×17

Act 3.0 Medicaid×17

Innovation in Pediatric Drugs Act×17

Retaining Access and Restoring Exclusivity×17

Step Therapy×17

MCM R&D Incentives×17

Vaccine Quality Measure×17

Vaccine Safety×17

Foreign Drug Data Protection Laws×17

Section 232×17

Diversity & Inclusion×16

Fair Investment Opportunities for Professional Experts Act×16

Decentralized Clinical Trials Drug Evaluation and Review×16

Patenting of Biological Inventions×16

Funding for Women's Health Research×16

Disease X Act×16

Gain of function×16

SAFE Risky Research Act×16

Capital Formation Incentives×16

Reference Pricing in Drug Reimbursement×16

World Intellectual Property Office×16

Pandemic Preparedness -R&D Funding for Medical Countermeasures×16

Generic Drug Entry×16

Generic Drug Application Review Reforms×16

Incentives for Generic Entry Issues×16

White House National Biodefense Strategy×15

Coverage and Reimbursement×15

Public Float Threshold Update Small Business Innovation Research×15

Tariffs Foreign Agricultural Biotechnology Laws and Regulations×15

Non-Opioid Analgesics Orphan Drug Issues×15

Patent Tax/fees×15

Section 317 Immunization Program×15

Vaccine Injury Compensation Program 340B Drug Discount Program×15

Compounding Pharmacies×15

Contract Manufacturing Ecosystem in the United States×15

Access to Innovative Treatments×15

PASTEUR ACT×15

FY 2025 Appropriations×14

Compulsory Licensing×14

28 U.S.C. 1498×14

Patent and copyright cases Data Privacy×14

Patent Reform×14

PTAB Reform×14

Administration for Strategic Preparedness and Response×14

Biomedical Advanced Research and Development Authority×14

Centers for Medicare and Medicaid×14

Food & Drug Administration×14

National Institutes of Health×14

National Defense Authorization Act 2027×14

Biosimilars Competition×14

Purple Book Draft×14

Consumer Data Privacy and Security Act×14

Diagnostics and Personalized Medicine Regulation and Oversight×14

PDUFA VII Implementation×14

PDUFA VIII Negotiations Drug Importation Drug Manufacturing×14

CMMI×14

NSC/OSTP priorities×14

Nucleic acid synthesis security and biotechnology governance×14

Pediatric Priority Review Voucher Pandemic Preparedness×14

Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products×14

Capital Market Enhancements×14

INNOVATE Act×14

Small Business Innovation and Economic Security Act×14

China Synthetic Biotech×14

US-China IP Provisions United Nations World Trade Organization×14

Monoclonal Antibody Coverage and Utilization×10

FY 2026 Appropriations×9

Value-Based Purchasing×9

Prohibiting Adversarial Patents Act×7

Executive Order on Access to Affordable Life-Saving Medications×7

Strengthening Innovation in Medicare and Medicaid Act×7

SUPPORT Act×7

Give Kids a Chance Act×7

American Innovation and R&D Competitiveness Act×7

Small Entity Update Act×7

American Innovation and Jobs Act×7

Bill to address patent thickets×6

Patent Eligibility Restoration Act×6

Biosimilar Copay×6

Safe, and Secure American Bioeconomy×6

Coverage of Accelerated Approval Products×6

HELP Copays Act×6

Expanding Access to Capital Act×6

Most Favored Nation×6

Prescription Drug Price Relief Act×6

Patent Thickets×5

COVID-19 Pricing Related Provisions×5

PBM Reform×5

Pediatric Priority Review Voucher Program×5

WHO Pandemic Preparedness Accord×5

Protected Classes×5

American Innovation Act×5

PROTECT 340B Act×5

FTC Orange Book Delisting Initiative×4

Protecting Americans Data from Foreign Adversaries Act×4

China Patent Reform×4

Decentralized Clinical Trials×4

FDA Hiring Flexibility Drug Importation Drug Manufacturing×4

Encouraging Innovation Benefit Design to Lower Costs for Seniors Act×4

Non-Opioid Analgesics×4

Temporarily Refundable R&D Credit×4

Administration Rebate Rule×4

Lower Costs×4

Countermeasures Injury Compensation Program×4

Vaccine Safety and Quality×4

340B Accountability Act×4

FY 2026 Appropriations for Specific Issues×4

Pandemic Preparedness×4

SUSTAIN 340B Act×4

Fair Prescription Drug Prices for Americans Act×4

Orphan Drug Issues×4

Finding Orphan-Disease Remedies with Antifungal Research and Development×4

One Big Beautiful Bill Act×4

PTO Proposed Rules on Terminal Disclaimer Practice×3

Patent Litigation Reform×3

Reasonable Pricing Clauses in BARDA Contracts×3

Tropical Disease Priority Review Voucher×3

House GOP RFI on Data Privacy×3

COVID-19 Lessons Learned×3

VICP×3

Coverage and Reimbursement Orphan Drug Issues×3

Orphan Drug Tax Credit Pandemic Preparedness×3

Medical Countermeasures PRV Reauthorization×3

BSUFA Negotiations×3

Compounded Medicines Drug Patenting×3

Medicaid Drug Rebate Program×3

Expensing of R&D Expenditures×3

Countermeasure Injury Compensation Fund Amendment Act×3

Global Fairness in Drug Pricing Act×3

ETHIC Act×3

ASPR×3

Creating Hope Reauthorization×3

PPRV×3

Emerging New Threats and×3

Medicare Negotiation and Competitive Licensing Act×3

China Synthetic Biotech Tariffs Trade Relations×3

Reasonable Pricing Clause Compulsory Licensing Data Privacy×2

Inventor Diversity for Economic Advancement×2

Orange Book Listing×2

World Health Organization×2

WHO Pandemic Preparedness Accord World Intellectual Property Office×2

340B Drug Discount Program×2

NDAA×2

MINI Act×2

Climate Change×2

Medicaid Drug Rebate Program Rule×2

More Cures Act×2

Banking Policy×2

Putting Investors First Act×2

Infectious Disease Therapies Research and Innovation Act×2

Net Operating Loss Advance Refunds×2

Amended Definition of Smaller Reporting Company×2

Small Issuer Exemption Small Business Innovation Research×2

Incentives for Sustainable Aviation Fuels×2

Sustainable Aviation Fuels Tax Credit×2

EU Ag-Biotech Policies×2

International Consistency of Regulation for Gene Edited Products×2

Korea Biotechnology Regulations×2

B5 Coalition on Supply Chain Resiliency×2

Biosimilars Red Tape Elimination Act×2

Cell & Gene Therapy×2

Most Favored Nation Foreign Drug Data Protection Laws×2

Precision Medicine Initiative Reimbursement and Coverage of Innovative Products×2

Improving Data Accessibility Through Advancements×2

Drug Evaluation and Review×2

Drug Importation Drug Manufacturing×2

Stronger Patents Act×2

Protecting Patient Access to Cancer and Therapies×2

More Transparency Act×2

VICP CICP×2

Family Vaccine Protection Act×2

R&D Payroll Credit×2

Net Operating Loss×2

Vaccines and Infectious Disease×2

US China IP Provisions×2

Dept of Commerce Patent Valuation Fee Proposal×2

National Defense Authorization Act 2026×2

Patentability of AI-Aided inventions Bayh-Dole Act/Tech Transfer×1

Invent Here×1

Make Here Act×1

March-In Rights×1

Title 35 to Address Infringements of Patents Claiming Biological Products×1

Protecting Consumer Access to Generic Drugs Act×1

USPTO Request for Comments: Experimental Use Defense 89 Fed×1

Reg 53963 Patenting of Biological Inventions×1

RESTORE Patent Rights Act×1

Program & Oversight×1

Biosecurity Infrastructure for Operational×1

American Pandemic Preparedness Plan×1

FY 2026 Appropriations Data Privacy×1

Clinical Trial Diversity Drug Evaluation and Review×1

Compounded Medicines×1

MCM PRV×1

CICP Funding for FDA×1

User Fees Funding for Health Resources and Services Administration×1

FY 2026 Appropriations Funding for National Institutes of Health×1

Advanced Research Projects Agency for Health×1

Funding for Womens Health Research International Reference Pricing Medicaid×1

General Cell & Gene Therapy×1

FY 2026 Appropriations Clinical Trial Data in China Data Privacy×1

General Diversity & Inclusion×1

Clinical Trial Diversity×1

General Drug Evaluation and Review×1

FY2025 Appropriations×1

PBN Reform×1

International Reference Pricing Foreign Drug Data Protection Laws×1

Regulatory Harmonization Funding for Antimicrobial Resistance×1

FY 2026 Appropriations International Reference Pricing Issues×1

Innovation and Pediatric Drugs Act×1

Impacting Emerging Companies×1

Regulatory Burden Capital Formation Incentives×1

JOBS Act 4.0×1

Market Liquidity Proposals×1

Public Float Threshold Update×1

SEC Small Business Forum×1

Small Business Capital Formation Enhancement Act×1

Mergers and Acquisitions Reform×1

Accredited Investor Certification Sarbanes Oxley Section 404×1

Adjusting the well-known seasoned issues×1

Definition to allow for a larger financing round using×1

General Pandemic Preparedness Renewable Chemicals/Bio-based Products×1

Tax Relief for American Families and Workers Act×1

R&D Payroll Credit Vaccine Injury Compensation Program×1

Medical Supply Chain Resiliency Act×1

Synthetic Biotech Pharmaceutical and Ag Biotech Tariffs US-China Trade Agreement×1

Ag-Biotech Provisions×1

IP Provisions World Health Organization×1

Patent Thickets Drug Pricing×1

Regulatory Harmonization Medicaid×1

March-In Rights Compulsory Licensing Data Privacy×1

Foreign Drug Data Protection Law×1

National Institute of Health×1

BARDA FY 2026 Appropriations for Specific Issues×1

Section 317 Immunization Program 340B Drug Discount Program×1

Accelerated Approval Access to non-human Primates×1

Climate Change Data Privacy×1

PDUFA×1

FDA Reform×1

Compounding & Counterfeit Medicines Drug Patenting×1

Rare Disease Pilot Program Pandemic Preparedness×1

Project Bio Shield×1

End Price Gauging for Medications Act×1

SMART Prices Act×1

VICP Biofuels and SAF×1

Carbo Capture Utilization Parity Capital Formation Incentives×1

Counterfeit Drug Monitoring Drug Pricing×1

United Nations×1

US-China Ag-Biotech Provisions×1

World Trade Organization×1

Food and Ag Organization×1

Pharmacy Benefit Managers×1

General Artificial Intelligence×1

March-In Rights Data Privacy×1

Skinny Labels×1

Patent Tax/fees Foreign Drug Data Protection Law×1

National Institute of Health FY 2026 Appropriations for Specific Issues×1

Reimbursement Cell & Gene Therapy Data Privacy×1

Clinical Trial Modernization×1

Drug Rebate Program Rule×1

Accelerated Approval Antimicrobial Resistance Artificial Intelligence×1

Prescription Drug Pricing for the People Act×1

Capital Market Enhancements Small Business Innovation Research×1

VICP/CICP Capital Formation Incentives×1

Most Favored Nation Foreign Agricultural Biotechnology Laws and Regulations×1

Intellectual Property Enforcement×1

National Institutes of Health FY 2026 Appropriations for Specific Issues×1

340B ACCESS Act×1

State Strategic Stockpile Act×1

Synthetic Nucleic Acid Synthesis Screening×1

PDUFA VIII Negotiations×1

Drug Manufacturing×1

Biologics Competition Act×1

Enhanced Access to Affordable Medicines Act×1

Most Favored Nation Pricing Opioid Crisis×1

Reimbursement and Coverage of Innovative Products×1

Administrative Rebate Rule×1

Impacting Emerging Companies Capital Formation Incentives×1

Public Float Threshold Update Sarbanes Oxley Section 404×1

CMMI Models×1

Intellectual Property International Enforcement×1

Bilateral Trade Negotiations×1

Word Health Organization×1

Issue mix

LDA general-issue codes weighted by activity count.

Health Issues18

Small Business18

Trade (domestic/foreign)18

Medicare/Medicaid3

Taxation/Internal Revenue Code3